Novacyt share price: should I buy the dip?

The Novacyt share price has fallen 40% in one month. Roland Head asks if it’s time to start buying despite uncertainty about post-Covid profits.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

The Novacyt SA (LSE: NCYT) share price hit a high of 1,190p in January, but it’s fallen sharply since. As I write, the shares are trading at around 700p, meaning this biotech stock has dropped 40% in just one month.

That’s a painful decline, but I think it’s worth keeping in context. Novacyt shares are still worth 400% more than they were one year ago, thanks to the success of its Covid-19 testing kits. These were developed rapidly at the start of the pandemic to meet surging demand.

An update today has confirmed the company is continuing to develop its Covid-19 product portfolio. However, we’ll have to wait until the second quarter of this year to learn more about Novacyt’s long-term plans.

For this reason, I think it’s fair to say there’s not much visibility on earnings once demand for Covid-19 products starts falling. As a potential investor, this is obviously a key risk. But I think it’s also an opportunity. If Novacyt can maintain its success, I believe it could become a more valuable business.

What happens after Covid-19?

The story so far is impressive. Novacyt’s sales rose from £11.5m in 2019 to £277m in 2020. Profits rose too. The company expects to report cash earnings before various costs of £187m for 2020. I’m not surprised Novacyt’s share price performed so well last year.

CEO Graham Mullis deserves full credit for his company’s impressive performance, in my view. But he still faces the challenge of making sure Novacyt’s newfound profitability doesn’t disappear when demand for Covid-19 products falls. Remember, until 2020, Novacyt had reported a loss every year since its flotation in 2012.

Mullis’ aim is to build “a sustainable, long-term diagnostics business.” One potential opportunity is Versalab, which aims to support private sector testing for infectious diseases. This service was launched in November 2020. It’s initially focused on Covid-19, but further tests are planned.

Novacyt share price: why I don’t think it’s cheap

Based on Novacyt’s expected earnings for 2020, the shares trade on about three times earnings. In my experience, when a company’s stock is rated this cheaply it means the market expects profits to fall.

That’s my view too. The company expects sales of Covid-19 products to be “strong throughout most of 2021.” But there’s little visibility beyond that.

This uncertainty is reflected in the latest forecasts from Novacyt’s house broker, which are available on its website. Earnings are expected to fall by around 17% in 2021, before dropping by around 65% in 2022.

Based on these forecasts, Novacyt’s current share price values the stock on about 12 times 2022 forecast earnings. That seems reasonable to me. But with no visibility on future earnings, it’s not cheap enough to persuade me to buy.

Novacyt’s technology has been a huge commercial and medical success during the pandemic. But without specialist medical knowledge, I’m not sure I can estimate how easily the firm’s will be able to expand into new areas.

For me, investing in a stock like this is too speculative. I won’t be buying, despite the possibility that Novacyt shares might be cheap today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

£1,000 invested in Lloyds shares 5 years ago is now worth…

Anyone who’s owned Lloyds shares over the last five years is probably laughing right now with impressive returns that crushed…

Read more »

A mature woman help a senior woman out of a car as she takes her to the shops.
Investing Articles

If a 50-year-old puts £500 a month into a SIPP, here’s what they could have by retirement

Investing £500 a month with a SIPP could build a pension pot worth £269,900 or quite a bit more over…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

How much do you need to invest in dividend stocks to target a £1,000 passive income?

Want to earn an extra £12,000 each year with dividend stocks? Zaven Boyrazian explores how much money investors need to…

Read more »

Finger pressing a car ignition button with the text 2025 start.
Investing Articles

FTSE shares for beginners: 2 solid picks to consider when starting a Stocks and Shares ISA

For those new to investing, Mark Hartley explains why he believes these two FTSE shares could help kickstart a resilient…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Here’s how to invest £10k to target a 7% dividend yield in 2025

Want to earn a lucrative and sustainable 7% dividend yield? Zaven Boyrazian explains the strategy he uses to generate plenty…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

I’m taking Warren Buffett’s advice as stocks reach record highs

Warren Buffett's wisdom is guiding my investing strategy in 2025 as stocks start reaching new all-time highs. Here's how I'm…

Read more »

Young woman carrying bottle of Energise Sport to the gym
Investing Articles

See what £10k invested in Legal & General shares in January is worth today

On the face of it, Legal & General shares have been a massive disappointment, says Harvey Jones. Yet the FTSE…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

This FTSE 100 stock yields 9.36% but I still wouldn’t touch it with a bargepole!

Harvey Jones is stunned by the massive amount of dividend income on offer from this FTSE 100 stock but is…

Read more »